# Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

> **NCT00588341** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Melanoma
- Skin Cancer
- Cancer

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00588341
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00588341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00588341, "Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00588341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*